On September 17, 2025, Elicio Therapeutics, Inc. reported that 99% of evaluable patients in their Phase 2 AMPLIFY-7P trial generated strong mKRAS-specific T cell responses, with an average increase of 145.3 times over baseline. This positive data reflects consistent immunogenicity and efficacy compared to earlier trials.